Loading...
XOSL
PHO
Market cap160mUSD
Jul 10, Last price  
59.00NOK
1D
0.51%
1Q
-1.67%
Jan 2017
40.48%
IPO
-60.14%
Name

Photocure ASA

Chart & Performance

D1W1MN
XOSL:PHO chart
P/E
—
P/S
2.95
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.60%
Rev. gr., 5y
15.74%
Revenues
533m
+1.37%
210,320,00099,006,000102,220,00048,428,000177,357,000115,568,000133,823,00083,616,000128,952,000134,717,000143,627,000150,911,000181,510,000281,556,000256,482,000360,540,000393,132,000500,657,000525,388,000532,580,000
Net income
-2m
L-68.42%
85,082,000-74,970,000-64,382,000312,382,00018,092,000-7,512,000-47,901,000-58,950,000-24,700,000-36,178,00035,309,000-34,697,000-36,708,00031,832,000-22,403,000-30,897,000-71,857,000979,000-4,810,000-1,519,000
CFO
38m
-50.24%
66,326,000-95,655,000-59,677,000317,444,00015,597,000-34,466,000-54,928,000-99,722,000-6,088,000-21,032,00019,193,000-23,593,000-24,124,00020,655,00015,585,00023,886,000-2,018,00048,307,00076,751,00038,189,000
Dividend
May 23, 20132 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Photocure ASA, a specialty pharmaceutical company established in Oslo, Norway in 1993, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing, distribution, and commercialization. The company's reach extends across the Nordic countries, major European markets like Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, as well as the United States. Key offerings include Hexvix/Cysview, which is used for the identification and ongoing care of bladder cancer. Additionally, Photocure is currently developing Cevira, a treatment designed for human papillomavirus (HPV) infections and precancerous lesions of the cervix. Its products are supplied to pharmaceutical wholesalers, pharmacies, and hospitals primarily through strategic licensing partnerships.
URL
https://photocure.com/
IPO date
May 29, 2000
Employees
87
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT